Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1271 to 1280 of 2733 total matches.

Yosprala - A Combination of Aspirin and Omeprazole

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017  (Issue 1513)
Yosprala: yo spra' lah SECONDARY PREVENTION — Aspirin irreversibly acetylates cyclooxygenase-1, blocking ...
The FDA has approved Yosprala (Aralez), a fixed-dose combination of delayed-release aspirin and immediate-release omeprazole, for secondary prevention of cardiovascular and cerebrovascular events in patients who are at risk of developing aspirin-associated gastric ulcers (≥55 years old or history of gastric ulcers). Yosprala is the first product to become available in the US that combines aspirin and a proton pump inhibitor (PPI).
Med Lett Drugs Ther. 2017 Jan 30;59(1513):25-6 |  Show IntroductionHide Introduction

In Brief: Tafamidis (Vyndaqel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy

   
The Medical Letter on Drugs and Therapeutics • Jan 27, 2020  (Issue 1590)
transthyretin stabilizer, in 2 different formulations (see Table 1) for treatment of adults with transthyretin ...
The FDA has approved tafamidis, an oral transthyretin stabilizer, in 2 different formulations (see Table 1) for treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Tafamidis is the first drug to be approved in the US for this indication. Patisiran (Onpattro), a transthyretin-directed small interfering RNA, and inotersen (Tegsedi), a transthyretin-directed antisense oligonucleotide, were both recently approved for hereditary transthyretin amyloid polyneuropathy.THE DISEASE — ATTR-CM is a progressive life-threatening disease caused by destabilization of the...
Med Lett Drugs Ther. 2020 Jan 27;62(1590):16 |  Show IntroductionHide Introduction

In Brief: A New Indication for Abemaciclib (Verzenio) (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
breast cancer at high risk of recurrence.1 It was previously approved for the same indication ...
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib (Verzenio – Lilly) has been approved by the FDA for use in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence.1It was previously approved for the same indication, but patients were also required to have a Ki-67 score ≥20%. About 70% of all breast cancers are HR-positive and HER2-negative. Ki-67 is a...
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e62-3   doi:10.58347/tml.2023.1673g |  Show IntroductionHide Introduction

In Brief: A New Indication for Tenecteplase (TNKase)

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 1727)
— Thrombolysis with IV alteplase is the first-line treatment for acute ischemic stroke.1 Tenecteplase ...
The tissue plasminogen activator (tPA) tenecteplase (TNKase – Genentech) has been approved by the FDA for treatment of acute ischemic stroke in adults. It is the second tPA to be approved in the US for this indication; alteplase (Activase) was approved in 1996. Tenecteplase was approved in 2000 to reduce the risk of death associated with acute ST-elevation myocardial infarction (STEMI).
Med Lett Drugs Ther. 2025 Apr 28;67(1727):71-2   doi:10.58347/tml.2025.1727d |  Show IntroductionHide Introduction

Prademagene Zamikeracel (Zevaskyn) for Recessive Dystrophic Epidermolysis Bullosa (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025  (Issue 1733)
1 vector-based gene therapy, is approved for once-weekly use in patients ≥6 months old ...
Prademagene zamikeracel (Zevaskyn – Abeona Therapeutics), an autologous cell sheet-based gene therapy, has been approved by the FDA for treatment of wounds in patients with recessive dystrophic epidermolysis bullosa. It is the first autologous cell sheet-based gene therapy to be approved in the US for this indication. Beremagene geperpavek gel (Vyjuvek), a herpes simplex virus type 1 vector-based gene therapy, is approved for once-weekly use in patients ≥6 months old with recessive dystrophic epidermolysis bullosa.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):e124-5   doi:10.58347/tml.2025.1733l |  Show IntroductionHide Introduction

In Brief: A New Indication for Uzedy

   
The Medical Letter on Drugs and Therapeutics • Jan 19, 2026  (Issue 1746)
) are also approved for treatment of bipolar I disorder (see Table 1).1,2 Table 1. Extended-Release ...
Uzedy, an extended-release, subcutaneous (SC) formulation of the second-generation antipsychotic drug risperidone, was approved by the FDA in 2023 for treatment of schizophrenia in adults. It has now been approved for use as monotherapy or in combination with lithium or valproate for maintenance treatment of bipolar I disorder in adults. Extended-release, intramuscular (IM) formulations of risperidone (Risperdal Consta and Rykindo) are also approved for treatment of bipolar I disorder (see Table 1).
Med Lett Drugs Ther. 2026 Jan 19;68(1746):15-6   doi:10.58347/tml.2026.1746e |  Show IntroductionHide Introduction

In Brief: Ranitidine Returns

   
The Medical Letter on Drugs and Therapeutics • Apr 13, 2026  (Issue 1752)
; soln = solution; susp = suspension 1. Approximate WAC for 30 days’ treatment with the lowest usual ...
The FDA has approved a new tablet formulation of the H2-receptor antagonist (H2RA) ranitidine from one manufacturer (VKT Pharma/Rising Pharma). It is only available by prescription. In 2020, the FDA requested that all formulations of ranitidine be withdrawn from the market because unacceptable levels of the nitrosamine compound N-nitrosodimethylamine (NDMA), a potentially carcinogenic contaminant, had been detected in ranitidine samples.
Med Lett Drugs Ther. 2026 Apr 13;68(1752):63-4   doi:10.58347/tml.2026.1752e |  Show IntroductionHide Introduction

Formoterol (Perforomist) for COPD

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 2007  (Issue 1274)
)-enantiomer of formoterol, was approved earlier this year for the same indication. 1 Drug class Long-acting ...
Formoterol fumarate (Perforomist - Dey), a long-acting beta2-agonist, was recently approved by the FDA as an inhalation solution for nebulization for maintenance treatment of bronchoconstriction associated with chronic obstructive pulmonary disease (COPD). Arformoterol (Brovana), the (R, R)-enantiomer of formoterol, was approved earlier this year for the same indication.
Med Lett Drugs Ther. 2007 Nov 19;49(1274):94-5 |  Show IntroductionHide Introduction

When a Statin Fails

   
The Medical Letter on Drugs and Therapeutics • Jul 27, 2009  (Issue 1317)
(1.8 mmol/L) a reasonable goal for patients at very high risk. LDL-C TARGETS — A meta-analysis of 58 ...
The National Cholesterol Education Program recommends that LDL-C be lowered to less than 100 mg/dL (2.6 mmol/L) and considers a value <70 mg/dL (1.8 mmol/L) a reasonable goal for patients at very high risk.
Med Lett Drugs Ther. 2009 Jul 27;51(1317):58-60 |  Show IntroductionHide Introduction

Primary Prevention of Ulcers in Patients Taking Aspirin or NSAIDs

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010  (Issue 1333)
have an especially high risk. 1 Drugs that have been tried for prevention of ulcers in patients taking NSAIDs ...
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high risk. Drugs that have been tried for prevention of ulcers in patients taking NSAIDs including H2-receptor antagonists, proton pump inhibitors (PPIs), aluminum- or magnesium-containing antacids, the prostaglandin misoprostol (Cytotec, and others), and antibiotics to eradicate H. pylori.Click here to view the free full...
Med Lett Drugs Ther. 2010 Mar 8;52(1333):17-9 |  Show IntroductionHide Introduction